Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Natera, Inc.
This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Natera common stock between February 26, 2020, and April 19, 2022, inclusive.
Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until June 27, 2022 to petition the court. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
According to a filed complaint, Natera, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s non-invasive prenatal test, Panorama, was not reliable and resulted in high rates of false positives; (2) the Company’s screening test for kidney transplant failure, Prospera, did not have superior precision compared to competing tests; (3) as a result of defendants’ false and misleading claims about Natera’s technology, the Company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, defendants’ statements about the company’s business, operations, and prospects lacked a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
1140 Avenue of the Americas
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887